Dapagliflozin for rheumatic musculoskeletal disease in patients with chronic kidney disease
Dapagliflozin is effective for rheumatic musculoskeletal disease patients with CKD for preventing deterioration of renal function. Antihypertensive treatment with ARB and inflammation control without tacrolimus was associated with a high likelihood of favourable response to dapagliflozin.
Authors
- Jun Kikuchi (ORCID: https://orcid.org/0000-0003-3231-8841)
- K. Hiramoto (ORCID: https://orcid.org/0009-0003-9278-7751)
- Hironari Hanaoka (ORCID: https://orcid.org/0000-0002-5172-1102)
- Shutaro Saito
- Yasushi Kondo (ORCID: https://orcid.org/0000-0002-1566-2088)
- Mitsuhiro Akiyama (ORCID: https://orcid.org/0000-0001-5075-8977)
- Yuko Kaneko (ORCID: https://orcid.org/0000-0003-2646-5765)
- Tatsuhiko Azegami
Institutions
- Keio University (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1093/mr/roae090
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72